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(gamma = 0.636, p = 0.04); the presence of LF with AGC – with
the Grade (gamma = 0.530, p = 0.03), histological type
(gamma = 0.726, p = 0.02) and the degree of dysplasia GM
(gamma = 0.833, p = 0.001). Multiple LF, focal LI and LF with AGC
bit more often observed at grade G3-4 and signet ring cell carci-
noma (SRCC) (LF 0%, 25%, 42.9% and 55.6%, p = 0.23, LI in50%,
42.9%, 100%, 66.7%, p = 0.07 and LF with AGC 12.5%, 0%, 50%,
28.6%, p = 0.17, respectively, when G1 , G2, G3-4 and SRCC) and
diffuse type gastric cancer (LF 20% and 50%, p = 0.12 in 60% and
81.2%, p = 0.23 and LF with AGC 10% and 41.2%, p = 0.07, respec-
tively, for the intestinal and diffuse type gastric cancer). Focal LI
and LF with AGC were more common in moderate and severe
dysplasia of the gastric epithelium (LI 58.3% and 84.6%, p = 0.14
and LF with AGC 50%, 8.3%, p = 0. 02).
A decrease in the three-year relapse-free survival in multiple
LF from 75% to 40%, p = 0.04 and in the presence of focal
LI – 83.3% to 57.9%, p = 0.17 were observed. In the presence of
focal LI, a decrease in the three-year overall survival from 100%
to 73.7% was also observed (p = 0.14).
The findings suggest that B-cells may be associated with the
factors of GC progression. It is important that the high density
of the diffuse B-lymphocytes was typical for early GC, whereas
the presence of LI and multiple LF in GM adjacent to tumor was
more often observed in diffuse type of GC, poorly differentiated
tumors and signet ring cell carcinoma We believed, that further
studies are needed for the understanding of the mechanisms
whereby the B-cell LI and LF may be related with the histology
type and Grade of GC.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.111
P11
Proteoglycans expression correlates with the phenotype of malignant
and non-malignant EBV-positive B-cell lines
A. Tsidulkoa,b,*, L. Matskovaa, L. Astakhovac, I. Ernberga,
E. Grigorievaa,b. aMTC, Karolinska Institute, Stockholm, Sweden,
bThe Institute of Molecular Biology and Biophysics, Novosibirsk,
Russian Federation, cKemerovo Institute of Food Science and
Technology, Kemerovo, Russian Federation
⇑
Corresponding author.
In vitro Epstein-Barr virus (EBV) infects B-cells resulting in
immortalization, In vivo the virus resides latent in resting
B-cells. Rarely the EBV-host cell interaction may contribute to
development of malignant lymphoma. It is well known that both
c-myc translocation and the viral infection are observed in
patients with EBV+ Burkitt’s lymphoma (BL). Proteoglycans (PGs)
are complex glycosylated proteins. They are key components of
ECM and play a critical role in cell–cell and cell–matrix interac-
tions. Disruptions of such interactions will affect B cell interac-
tion with surrounding stroma and may thus perturb the cell
phenotypes. The purpose of this study was to investigate
expressinon of proteoglycans in EBV+ cell lines with different ori-
gins and phenotypes.
We analysed the expression of 12 of the main proteoglycans in
primary B cells, lymphoblastoid cell lines (LCLs) generated by EBV
infection of normal human B cells in vitro and EBV-positive BL cell
lines. An EBV-negative BL cell line was used for reference.
According to RT-PCR analysis, primary B-lymphocytes
expressed different PGs, mainly serglycin, CD44, perlecan and
syndecan-1. The high expression of PGs in normal B cells proba-
bly reflects interactions of these cells with the neighbouring cells
and microenvironment. B cell lines which carry EBV, in general,
showed lower levels of PGs. The PGs expression pattern was sim-
ilar in LCLs and in primary B cells, however, distinguished by high
levels of perlecan and serglycin and low expression of CD44 in
LCLs. BL cells showed the most significant down-regulation of
PGs compared to primary B cells. Therewas a correlation between
the type of EBV latency program, and PGs expression. Serglycin
was expressed at a low levels in BL-cells with EBV latency
III-program compared to LCLs, while in EBV latency I BL cells both
serglycin and perlecan were down-regulated.
Cells with latency I-program show general hypermethylation
of the cellular genome in contrast to cells with latency
III-program. Thus we explored the possibility of epigenetic
regulation of the PG-coding genes by treating cells with
50-deoxyazacytidine (5-AzaC, a demethylating agent) and Tricho-
statin A (TSA, a chromatin structure modulator). There was no
significant change in PGs expression upon this treatment in LCLs
or in EBV latency III BL cells, while EBV latency I BL cells showed
up-regulation of several PGs. This suggests that PGs expression is
at least partly regulated by epigenetic mechanisms. Interestingly
EBV latency is also partly regulated at the epigenetic level.
Similar trends were observed for the key ECM components
(collagen 1A1, fibronectin and elastin). Normal B lymphocytes
expressed collagen, fibronectin and elastin, whereas LCLs and
BL cells showed no expression of these. Treatment of these cells
with 5-AzaC or TSA resulted in similar changes in PGs expression
patterns. Up-regulation of ECM components was detected only in
EBV latency I BL cells.
Taken together, our data show that proteoglycans are
expressed in primary B lymphocytes whereas they are not or only
partly expressed in EBV-carrying cell lines, depending on their
latency program. Expression of PGs in latency I BL cells is silenced
due to hypermethylation, but by another mechanim in latency III
BL cells. These results show that PGs expression patterns follow
the EBV latency programs . It will be highly interesting to further
investigate if EBV and its transformation associated genes are
directly involved in control of PGs, as well as how PGs may con-
tribute to major phenotypic properties of EBV-carrying cell lines,
such as adhesion, migration and growth in soft agarose – a prop-
erty associated with the malignant phenotype of BLs.
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